Online Inquiry
Phospho-p44/42 MAPK (Thr202/Tyr204) ELISA Kit
SPK-00298
| Size | Price |
| 1 X 96T | Online Inquiry |
| 5 X 96T | Online Inquiry |
| 10 X 96T | Online Inquiry |
| More Options | Online Inquiry |
| Target Information | |
|---|---|
| Target Name | Erk1/2 |
| Gene Abbr. | MAPK3 |
| Gene ID | 5595 |
| Full Name | mitogen-activated protein kinase 3 |
| Alias | ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A |
| Introduction | Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines , and research investigators consider it an important target in the diagnosis and treatment of cancer. Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK and the transcription factor Elk-1. p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs, along with MEK inhibitors, such as U0126 and PD98059. |
| Usage | |
|---|---|
| Application | ELISA |
| Reactivity | |
| Sensitivity | This kit detects endogenous levels of p44/42 MAPK when phosphorylated at Thr202/Tyr204. |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.